BPC-157 + TB-500

Why these are combined

BPC-157 works systemically through growth-hormone signaling and neuroprotection; TB-500 drives angiogenesis and fibroblast activation. A rat Achilles-tendon study tested the combination directly and found both peptides improved healing, but not clearly more than either one alone. People stack them anyway because the mechanisms are different enough to seem complementary.

Mechanism & pharmacokinetics

The two don't compete for the same receptors, which is the whole logic of pairing them: BPC-157 works through upregulated growth-factor receptor expression and nitric-oxide signaling, while TB-500 (a Thymosin Beta-4 fragment) works through actin regulation and cell migration. Their pharmacokinetics differ sharply, though. BPC-157 has a short plasma half-life, estimated at around 40 minutes in vitro, which is why community protocols dose it daily or even twice daily. TB-500/Tβ4 behaves differently: it binds and sequesters actin, and its downstream effects on cell migration and angiogenesis are reported to persist well beyond its own plasma clearance, which is the rationale behind loading-phase-then-taper protocols (frequent dosing for the first weeks, then dropping to once or twice weekly). No study has measured the two given together, so this is mechanistic reasoning from each peptide's individual data, not a tested combination.

Citations

• Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study — Biçer et al. 2026
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Mayfield et al. 2026

Typical community protocol

Commonly dosed as BPC-157 at 200-500 mcg daily (often 250 mcg) and TB-500 at 2-4 mg weekly for 4-12 weeks, subcutaneous injection, often staggered to minimize injection frequency.

Safety notes